ESMO 2021 | KEYNOTE-716: safety profile and results of pembrolizumab for melanoma
Jason J. Luke, MD, FACP, University of Pittsburgh, Pittsburgh, PA, discusses the results of the KEYNOTE-716 trial of pembrolizumab for high-risk melanoma. Patients with stage 2B and 2C melanoma treated with pembrolizumab had a 35% reduction in recurrence and a 40% reduction in distant organ metastases. Additionally, quality of life was found to be the same between patients treated with pembrolizumab and those treated with a placebo. This interview took place at the European Society for Medical Oncology (ESMO) 2021 congress.
Disclosures
Dr Luke reports DSMB: Abbvie, Immutep. Scientific Advisory Board: (no stock) 7 Hills, Fstar, Inzen, RefleXion, Xilio (stock) Actym, Alphamab Oncology, Arch Oncology, Kanaph, Mavu, Onc.AI, Pyxis, Tempest.
Dr Luke reports consultancy with compensation: Abbvie, Alnylam, Avillion, Bayer, Bristol-Myers Squibb, Checkmate, Codiak, Crown, Day One, Eisai, EMD Serono, Flame, Genentech, Gilead, HotSpot, Kadmon, KSQ, Janssen, Ikena, Immunocore, Incyte, Macrogenics, Merck, Mersana, Nektar, Novartis, Pfizer, Regeneron, Ribon, Rubius, Silicon, Synlogic, Synthekine, TRex, Werewolf, Xencor.
Dr Luke reports research support: (all to institution for clinical trials unless noted) AbbVie, Agios (IIT), Astellas, Astrazeneca, Bristol-Myers Squibb (IIT & industry), Corvus, Day One, EMD Serono, Fstar, Genmab, Ikena, Immatics, Incyte, Kadmon, KAHR, Macrogenics, Merck, Moderna, Nektar, Next Cure, Numab, Pfizer (IIT & industry) Replimmune, Rubius, Scholar Rock, Synlogic, Takeda, Trishula, Tizona, Xencor/
Dr Luke reports patents: (both provisional) Serial #15/612,657 (Cancer Immunotherapy), PCT/US18/36052 (Microbiome Biomarkers for Anti-PD-1/PD-L1 Responsiveness: Diagnostic, Prognostic and Therapeutic Uses Thereof)
